Eli Lilly (LLY) continues to dominate the weight-loss drug market, positioning itself for significant growth amid rising demand. Despite concerns over its high valuation—trading at 25.7x forward earnings compared to the 17x average for healthcare stocks—Morgan Stanley’s analyst Terence Flynn has reaffirmed a bullish outlook, maintaining an overweight rating with a price target of $1,327, suggesting a potential 52% upside. This optimism is fueled by expectations of substantial sales from its weight-loss products, including the newly launched Foundayo and Zepbound, projected to generate $31 billion in U.S. sales next year.
However, Eli Lilly faces challenges, notably CVS Health’s recent decision to drop coverage of Zepbound in favor of Novo Nordisk’s Wegovy, which could impact adoption rates. Despite these headwinds, the company’s robust pipeline, including promising candidates like retatrutide, and its expansion into other therapeutic areas, bolster its long-term prospects. Investors should consider Eli Lilly as a compelling opportunity for growth and income, given its strong performance and dividend history.
Source: fool.com